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Objectives: Alterations in the PhoPQ two-component regulatory system may be associated with colistin resist-
ance in Klebsiella pneumoniae. MgrB is a small transmembrane protein produced upon activation of the PhoPQ
signalling system, and acts as a negative regulator on this system.We investigated the role of the MgrB protein as
a source of colistin resistance in a series of K. pneumoniae.
Methods: Colistin-resistant K. pneumoniae isolates were recovered from hospitalized patients worldwide (France,
Turkey, Colombia and South Africa). The mgrB gene was amplified and sequenced. A wild-type mgrB gene was
cloned and the corresponding recombinant plasmid was used for complementation assays. Clonal diversity was
evaluated by MLST and Diversilab analysis.
Results: Of 47 colistin-resistant isolates, 12 were identified as having a mutated mgrB gene. Five clonally unre-
lated isolates had anmgrB gene truncated by an IS5-like IS, while one clone also harboured an insertional inacti-
vation at the exact same position of the mgrB gene, but with ISKpn13. Another clone harboured an insertional
inactivation due to ISKpn14 at another location of themgrB gene. Two clonally related isolates harboured an IS
(IS10R) in the promoter region ofmgrB. Finally, three clonally unrelated isolates harboured substitutions leading
to anticipated stop codon in the MgrB protein. Complementation assays with a wild-type MgrB protein restored
full susceptibility to colistin for all colistin-resistant isolates identified with qualitative or quantitative MgrB
modifications.
Conclusion: The inactivation or down-regulation of themgrB genewas shown to be a source of colistin resistance
in K. pneumoniae. Interestingly, identical genetic events were identified among clonally unrelated isolates.
Keywords: gene inactivation, PhoPQ regulatory system, polymyxin, Klebsiella pneumoniae
Introduction
Colistin and other polymyxins are cationic peptides synthetized
by a Gram-positive species, namely Paenibacillus polymyxa.
Those antibiotics act by disrupting the negatively charged outer
membranes of Gram-negative bacteria.1 Colistin is now often
considered as the last option to treat multidrug-resistant
Gram-negatives, and in particular carbapenemase-producing
Enterobacteriaceae and Acinetobacter baumannii.2 Klebsiella
pneumoniae is the enterobacterial species in which acquisition
of a carbapenemase is most frequently identified, and therefore
multidrug-resistant K. pneumoniae are increasingly reported.3
Colistin is consequently increasingly used in endemic areas
for carbapenemase-producing K. pneumoniae, and reports of
colistin-resistant isolates in that species are on the rise.4
Alterations in the two-component regulatory systems
PhoPQ and PmrAB,5,6 as well as inactivation of the mgrB gene,7,8
have been reported to be involved in polymyxin resistance in
K. pneumoniae. The sensor kinase PhoQ is an integral membrane
protein whose periplasmic domain is involved in signal detection.
It is activated by low extracellular magnesium (Mg2+), acidic pH
(pH 5.5) or the presence of cationic antimicrobial peptides.9,10
Upon activation, it activates PhoP by phosphorylation. Then
PhoP activates PmrHFIJKLM expression, directly by binding to
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the pmrHFIJKLM promoter, and indirectly via PmrD-dependent
activation of the PmrA protein also binding to the pmrHFIJKLM
promoter.11 The pmrHFIJKLM operon (also named pmrF, pbg or
arn operon) encodes enzymes responsible for the synthesis and
transfer of 4-amino-4-deoxy-L-arabinose (LAra4N). The addition
of this cationic product (LAra4N) to lipid A leads to resistance to
polymyxins by modification of the lipopolysaccharide target.10
MgrB, a small regulatory transmembrane protein of 47 amino
acids, is produced upon activation of the PhoPQ signalling
system.12 Through interactions between the MgrB protein and
the periplasmic domain of PhoQ, MgrB negatively regulates the
PhoP/PhoQ system. MgrB spans the inner membrane and represses
PhoP phosphorylation, probably by inhibiting the PhoQ kinase
activity or stimulating phosphatase activity. Phosphorylation of
PhoP increases transcription of themgrB gene. MgrB is consequently
part of a negative feedback loop in the PhoQ/PhoP signalling
circuit.
Two recent pioneering studies showed that insertional inacti-
vations in the mgrB gene were the source of acquired resistance
to colistin in K. pneumoniae.7,8 Such inactivation leads to an
up-regulation of the PhoPQ system, leading to the up-regulation
of the pmrHFIJKLM operon, and ultimately to colistin resistance.
The aim of our study was to analyse a collection of 47 colistin-
resistant K. pneumoniae strains recovered from different geo-
graphical areas in order to identify whether there were alterations
in the mgrB gene that may explain the resistance to colistin.
Material and methods
Bacterial strains
Forty-seven colistin-resistant K. pneumoniae clinical isolates
recovered from hospitalized patients in France, Turkey, Colombia
and South Africa were investigated. The isolates were identified
using the API 20E system and the MALDI-TOF technique
(bioMe´rieux, La Balme-les-Grottes, France).
Antimicrobial susceptibility assays
MICs were determined using Etest strip (bioMe´rieux) according to
the manufacturer’s instructions on Mueller–Hinton agar plates
(BioRad, Marnes-la-Coquette, France) with a 0.5 McFarland inocu-
lum in sterile water, and interpreted as indicated by the EUCAST
guidelines (EUCAST breakpoint tables for interpretation of MICs
and zone diameters, version 3.1, 2013; http://www.eucast.org).
Following the EUCAST breakpoints, isolates with MICs of colistin
≤2 mg/L were categorized as susceptible, although those with
MICs .2 mg/L were resistant.
PCR amplification and sequencing
Whole-cell DNA was extracted using the QIAquick kit (Qiagen,
Courtaboeuf, France) according to the manufacturer’s instruc-
tions. The entire mgrB gene was amplified with specific oligo-
nucleotide primers mgrB-extF (5′-TTAAGAAGGCCGTGCTATCC-3′,
position 252 with respect to the mgrB start codon in order to
include the promoter sequences) and mgrB-extR (5′-AAGGCG
TTCATTCTACCACC-3′, located after the stop codon) as published.7
PCR products were analysed by gel electrophoresis and sequenced
with an automated ABI 3100 sequencer (Applied Biosystems,
Foster City, CA, USA). The nucleotide and deduced protein
sequences were analysed at the National Center for Bio-
technology Information web site (www.ncbi.nlm.nih.gov) using
the Basic Local Alignment Search Tool program. ISs were analysed
using the IS finder web site (www-is.biotoul.fr). Detection of
b-lactamase genes was performed with primers as described
previously.13
Complementation assays
The entiremgrB gene from the colistin-susceptible K. pneumoniae
reference strain ATCC 53153 (MIC at 0.125 mg/L) was amplified
by PCR using the 2X Phusion HF Master Mix (Finnzymes, Life
Technologies, Illkirch, France) and primers mgrB-extF/mgrB-extR.
The partial and therefore non-codingmdh sequence (supposed
to encode a malate dehydrogenase) was PCR amplified with pri-
mers mdh-extF (5′-CCCAACTCGCTTCAGGTTCAG-3′)/mdh-extR
(5′-CCGTTTTTCCCCAGCAGCAG-3′).
The amplified fragments were respectively cloned into the
high-copy plasmid pCR-BluntII-TOPO (Invitrogen, Illkirch, France)
and the resulting plasmids pTOPO-mgrB and pTOPO-mdh
(encoding resistance to zeocin) were separately transformed
into the colistin-resistant isolates by electroporation. Electro-
transformants were selected by overnight incubation at 378C on
Mueller–Hinton agar supplemented with 100 mg/L of zeocin.
The colistin MICs of the K. pneumoniae transformants were mea-
sured using Etest.
Since pCR-BluntII-TOPO is a high-copy plasmid that may lead
to a too high overexpression of the corresponding cloned genes
and therefore constitute a bias in our experiments, we modified
this plasmid backbone by replacing its pUCOri replication origin
locus with the p15a replication of the low-copy plasmid
pACYC184, leading to a new plasmid backbone we named
pLow-TOPO. The exact same inserts were inserted into that low-
copy plasmid and further experiments performed as above.
Genotyping by MLST and Rep-PCR (Diversilabw)
MLST was carried out with seven standard housekeeping loci
(rpoB, gapA, mdh, pgi, phoE, infB and tonB) according to
Diancourt et al.14 Sequence types were analysed using the data-
base provided by the Institut Pasteur, Paris, France (http://www.
pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.html).
DNAwas extracted using UltraClean Microbial DNA Isolation kit
(Mobio, Saint-Quentin-en-Yvelines, France). Genotyping was eval-
uated by rep-PCR, using the Diversilab Klebsiella kit (bioMe´rieux)
following the manufacturer’s recommendations. Amplicons
were separated by microfluidic chip with the Agilent 2100
Bioanalyzer and the rep-PCR fingerprints were analysed with the
coupled software.
Results and discussion
Analysis of the mgrB gene sequences
The entire mgrB gene of the 47 colistin-resistant isolates was
amplified by PCR, and further sequence analysis of the amplicons
showed that nine isolates generated a larger-in-size amplicon
compared with a wild-type isolate. Identification of different
fragment lengths compared with those obtained with a
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colistin-susceptible strain (T1a) suggested the insertion of DNA
sequences into the coding sequence or in the upstream vicinity
of themgrB gene in those nine isolates. Sequencing of the ampli-
cons revealed that insertional inactivations had occurred at differ-
ent positions into the mgrB gene in seven isolates and into the
putative mgrB promoter in two isolates (Table 1). In addition,
sequence analysis revealed a premature stop codon occurring in
the sequence of mgrB for three additional isolates (Table 1).
Characteristics of isolates
The nine colistin-resistant isolates for which different-in-size
amplicons were obtained were of different geographical origins,
with six isolates from Colombia, two isolates from France and a
single isolate from Turkey (Table 1). MICs of colistin for those iso-
lates ranged from 4 to 24 mg/L (Table 1).
Truncation of mgrB by an IS5-like IS is a key mechanism
leading to colistin resistance
In five isolates, the mgrB was truncated by the same 1195 bp IS.
This IS was closely related (93% nucleotide identity) to IS5, with
both transposases sharing 99%amino acid identity (3 substitutions
out of 326 amino acids).15 Surprisingly, the IS5-like insertion identi-
fied in themgrB gene of those five distinct isolates always targeted
the same location, between nucleotides 74 and 75 of the mgrB
sequence, and was always in the same orientation (Table 1).
Rep-PCR (Diversilabw) analysis revealed that four out of those five
isolates were clonally unrelated, with only isolates C9 and C10
from Colombia being related, but different from all others
(Figure 1a, Table 1). More surprisingly, this IS5-like element was
identical to that recently identified in a colistin-resistant and
KPC-3-producing K. pneumoniae isolate.7 In that study, Cannatelli
et al.7 showed that the insertion of this IS5-like element into the
mgrB gene was involved in resistance to colistin. Surprisingly, this
IS5-like sequence was inserted at the exact same location com-
pared with the isolates of our study, but in the opposite orientation
(Figure 2b). A 4 bp target site duplication (TTAA), being the signature
of the transposition event, was systematically identified at each
extremity of the IS5-like element in all isolates (Figure 2b and c).
The colistin-susceptible isolate T1a and the resistant-colistin
isolate T1b recovered from a same patient, respectively, before
and after colistin therapy were found to be clonally related, as
expected (Figure 1a, Table 1). Isolate T1a harboured a wild-type
mgrB gene, indicating that insertion of the IS5-like element prob-
ably occurred in vivo and that the resistant isolate T1b had prob-
ably been selected under antibiotic selective pressure. Altogether,
these data concur with the fact that the mgrB inactivation med-
iates acquired resistance to colistin.
Truncation of the mgrB gene by diverse ISs identified in
colistin-resistant isolates
In isolate C21, an IS of 1148 bp named ISKpn13 and belonging to
the IS5 family was identified at nucleotide position 74 (Figure 2d,
Table 1), which corresponds to the exact same position where the
IS5-like targeted themgrB gene in five other isolates (see above).
ISKpn13 shared,30% nucleotide identity with the IS5-like elem-
ent, their respective transposase proteins sharing 56% amino acid
identity.16 Detailed analysis of their inverted repeats revealed that Ta
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the first 11 bp were identical. In addition, the exact same target
site duplication (TTAA) was identified on each extremity of
ISKpn13. Thus, nucleotide positions 74–75 in mgrB might consti-
tute a hot spot of integration for ISs belonging to the IS5 family.
In isolate C22, a truncation of the mgrB gene was also found.
This truncation resulted from the insertion of ISKpn14, a 768 bp IS
belonging to the IS1 family that does not share any significant
identity with IS5-like elements.17 That insertion occurred between
nucleotide positions 127 and 128 in the mgrB gene, and gener-
ated a 9 bp target site duplication (CTATTAATA) (Figure 2e, Table 1).
Truncation of mgrB by a premature stop codon identified
in three isolates
In three isolates, a premature stop codon was identified in the
sequence of the mgrB gene, leading to truncated proteins. The
full-length MgrB protein that is usually 47 amino acids in wild-
type isolates was therefore only 29 amino acids long in two un-
related isolates (15I5 and C11), and it was 27 amino acids long
in another isolate (Sa) (Table 1). Those amino acid substitutions
were probably leading to a non-functional MgrB protein, and
therefore were probably the source of colistin resistance.
Modification of the mgrB gene expression through the
insertion of IS elements
In isolates C1 and C2, the IS10R element (also called ISVsa5) was
identified between nucleotide positions 227 and 226 when
referring to the start codon ofmgrB as+1. This 1152 bp IS belongs
to the IS10 group, which itself belongs to the IS4 family.18 This
suggested that insertion of IS10R might have influenced the
expression of mgrB in those two isolates. Analysis of the genetic
relationship of isolates C1 and C2 performed by rep-PCR
(Diversilabw) showed that they were clonally related (Figure 1b,
Table 1).
In silico analysis of the sequence located upstream of a wild-
type mgrB gene revealed putative promoter sequences made
from 235 [TTTTGA] and 210 [TAAACT] boxes separated by
17 bp (Figure 3). The insertion of IS10R actually targeted the
DNA sequence located between the mgrB start codon and this
promoter region. Therefore, itmay be hypothesized that this inser-
tion led to an inactivation of this promoter with respect to the
20C9
11I8
C10
C9
T1b
T1a
C2
C1
1
2
75 80 85
% Similarity
99.5 99.6 99.7 99.8 99.9100
% Similarity
Similarity line: 94.3%
90 95 100
(a)
(b)
Figure 1. Dendrogram analysis and virtual gel images of rep-PCR
fingerprint patterns of (a) the five K. pneumoniae isolates in which
insertion of IS5-like into their mgrB gene has been identified; (b) the two
K. pneumoniae isolates in which insertion of IS10R upstream of mgrB
has been identified.
mgrB
IS5-like74 bp 70 bp
(a)
(b)
(c)
(d)
(e)
ISKpn1374 bp 70 bp
ISKpn14
CTATTAATA CTATTAATA
127 bp 17 bp
IS5-like
TTAA
TTAA
74 bp 70 bp
TTAA
TTAA
TTAA TTAA
1195 bp
1195 bp
1148 bp
768 bp
Figure 2. Schematic representation of the different insertion events
identified in the mgrB gene. (a) The intact mgrB gene as found in
wild-type isolates and isolate T1a; (b) mgrB truncated by IS5-like as
identified by Cannatelli et al.7; (c) mgrB truncated by IS5-like in isolates
11I8, 20C9, C9, C10 and T1b; (d) mgrB truncated by ISKpn13 in isolate
C21; (e) mgrB truncated by ISKpn14 in isolate C22. The target site
duplications are underlined. The left and right inverted repeats of each
IS are represented as black triangles.
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mgrB expression, the corresponding 235 and 210 sequences
being too far distant from the gene (Figure 3). That might explain
a decrease in or even lack of expression of themgrB gene, leading
to a low production of the corresponding protein and conse-
quently the acquired resistance to colistin.
Complementation experiments
Complementation of three colistin-resistant isolates (one identi-
fiedwith an IS element inserted into themgrB gene, one identified
with an IS element inserted into the mgrB promoter region and
one identified with a truncated mgrB gene) was performed.
These three isolates were representative of the different isolates
identified in this study. For that purpose, these three isolates
were transformed with the high-copy recombinant plasmid
pTOPO harbouring a wild-type mgrB gene (plasmid pTOPO-
mgrB) in order to provide the wild-type MgrB protein in trans. As
a result, a full susceptibility to colistin was fully recovered in
those three isolates (Table 2). As expected, transformation with
plasmid pTOPO-mdh used as negative control did not restore sus-
ceptibility to colistin. Similar if not identical results were actually
obtained when using the low-copy plasmid pLow-TOPO harbour-
ing the same inserts (Table 2). Those results confirmed that resist-
ance to colistin was related to the lack of MgrB. Although we
cannot exclude associated mechanisms in these K. pneumoniae
isolates, results of this complementation assays assessed the
role of MgrB in acquired colistin resistance.
Conclusions
The truncation of the mgrB gene was recently identified as a
source of acquired colistin resistance in K. pneumoniae. Here we
further assessed the critical role of modifications in MgrB produc-
tion in colistin resistance. By identifying a series of truncatedmgrB
genes among colistin-resistant K. pneumoniae isolates, we further
confirmed that this gene might be considered as a key target for
development of colistin resistance in K. pneumoniae. It is note-
worthy that eight of those isolates belonged to ST258, which is
the most widespread clone producing KPC-type carbapenemase
worldwide. Mutations were observed inside the coding sequence
of themgrB gene, but also in the promoter region, probably lead-
ing to a reduced expression of the mgrB gene in the latter case.
Overall, those findings further confirm that MgrB makes a crucial
contribution to the susceptibility to colistin usually observed in
K. pneumoniae.
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